https://sarissa-biomedical.com/ Translating biomedical research into everyday care en Mon, 09 Nov 2026 15:12:12 GMT https://sarissa-biomedical.com/between-needle-and-report-uk-blood-sample-pathway/ https://sarissa-biomedical.com/between-needle-and-report-uk-blood-sample-pathway/ A routine blood test is often described as a single event, yet it is a sequence of handoffs, checks and queues. This article maps the journey from GP surgery to laboratory report in 2026, showing where delays, rejections and interpretation gaps can emerge and what clinicians and patients can reasonably ask. Sarissa Biomedical Clinical Testing Literacy Mon, 09 Nov 2026 14:03:36 GMT https://sarissa-biomedical.com/after-launch-post-market-surveillance-diagnostic-care/ https://sarissa-biomedical.com/after-launch-post-market-surveillance-diagnostic-care/ A diagnostic or health-software product does not stop changing once it reaches routine care. This article examines how post-market problems surface in UK practice, what MHRA and NHS reporting routes require, and why a transparent correction can strengthen rather than undermine clinical trust. Sarissa Biomedical Diagnostics and Primary Care Mon, 09 Nov 2026 05:42:33 GMT https://sarissa-biomedical.com/address-on-sample-tube-local-validation-home-diagnostic-kits/ https://sarissa-biomedical.com/address-on-sample-tube-local-validation-home-diagnostic-kits/ A laboratory assay can be analytically sound and still make a poor home-testing pathway. This article sets out why local validation matters for at-home blood, saliva and urine kits in the UK, and offers a plain-English checklist for clinicians, commissioners and consumers. Sarissa Biomedical Clinical Testing Literacy Mon, 09 Nov 2026 02:03:54 GMT https://sarissa-biomedical.com/beyond-the-checkbox-digital-triage-uk-primary-care/ https://sarissa-biomedical.com/beyond-the-checkbox-digital-triage-uk-primary-care/ Digital triage and AI symptom checkers are now part of the NHS front door. They can manage demand and surface red flags, but they cannot ask the questions that make a clinical conversation safe. A practical framework for 2026. Sarissa Biomedical Diagnostics and Primary Care Sun, 08 Nov 2026 18:36:15 GMT https://sarissa-biomedical.com/ward-without-walls-point-of-care-testing-care-homes/ https://sarissa-biomedical.com/ward-without-walls-point-of-care-testing-care-homes/ Rapid tests in nursing homes could keep frail residents out of hospital and speed treatment. The barriers are less about the technology than about training, funding and governance. Sarissa Biomedical Clinical Testing Literacy Sun, 08 Nov 2026 18:36:15 GMT https://sarissa-biomedical.com/blood-test-caveats-clinical-conversation/ https://sarissa-biomedical.com/blood-test-caveats-clinical-conversation/ A blood result is a measurement under conditions, not a verdict, and the conditions matter most when the number looks normal. This practical listicle sets out five interpretive traps — haemolysis, fasting status, reference-range drift, incidental findings and repeat-testing thresholds — with consultation scripts for explaining uncertainty without undermining useful testing. Sarissa Biomedical Clinical Testing Literacy Sun, 08 Nov 2026 13:49:51 GMT https://sarissa-biomedical.com/adoption-by-design-validated-diagnostic-routine-nhs-care/ https://sarissa-biomedical.com/adoption-by-design-validated-diagnostic-routine-nhs-care/ A diagnostic can perform well in study conditions and still fail to change care if the route into practice is never designed. This analysis sets out why NICE evaluation, ICB budget silos, pathway ownership and the missing business case remain the real adoption gate — and the questions innovators, clinicians and commissioners should ask in 2026. Sarissa Biomedical Diagnostics and Primary Care Sun, 08 Nov 2026 13:49:51 GMT https://sarissa-biomedical.com/negative-multi-cancer-blood-test-all-clear-uk-2026/ https://sarissa-biomedical.com/negative-multi-cancer-blood-test-all-clear-uk-2026/ Multi-cancer early detection tests are now reachable through private clinics and NHS evaluation studies, and patients increasingly arrive at general practice holding a result they read as reassurance. This analysis unpacks sensitivity, positive predictive value and interval cancers, and sets out the questions that should accompany a 'clear' result before anyone relaxes. Sarissa Biomedical Diagnostics and Primary Care Sun, 08 Nov 2026 09:48:52 GMT https://sarissa-biomedical.com/wearable-heart-rhythm-alert-gp-ae-checklist-uk-2026/ https://sarissa-biomedical.com/wearable-heart-rhythm-alert-gp-ae-checklist-uk-2026/ Smartwatches and rings now generate cardiac and breathing notifications for people who feel entirely well, and a growing share of those people present to general practice or emergency departments holding a phone. This opinion piece examines the distance between a consumer signal and a clinical diagnosis, and offers parallel checklists for clinicians and patients. Sarissa Biomedical Public Health Surveillance Sun, 08 Nov 2026 09:48:52 GMT https://sarissa-biomedical.com/recruitment-not-representation-trial-evidence-nhs-2026/ https://sarissa-biomedical.com/recruitment-not-representation-trial-evidence-nhs-2026/ A recruitment push can raise trial numbers without making trial evidence more relevant to the communities the NHS serves. This opinion piece argues that site selection, participant burden and digital access determine who is represented, and sets out practical questions for clinicians, researchers and patients in 2026. Sarissa Biomedical Public Health Surveillance Sun, 08 Nov 2026 01:53:49 GMT https://sarissa-biomedical.com/beyond-the-badge-vetting-health-tech-claims-2026/ https://sarissa-biomedical.com/beyond-the-badge-vetting-health-tech-claims-2026/ Health-tech marketing is full of reassuring phrases, but confidence should come from evidence rather than vocabulary. This patient-facing guide explains how to check claims, understand UK regulatory and advertising basics, and use a practical checklist before buying a home health device or app. Sarissa Biomedical Diagnostics and Primary Care Sun, 08 Nov 2026 01:53:49 GMT https://sarissa-biomedical.com/community-pharmacy-diagnostics-uk-evidence-validation-2026/ https://sarissa-biomedical.com/community-pharmacy-diagnostics-uk-evidence-validation-2026/ The 2026 push to place more biomarker testing and chronic disease monitoring in community pharmacies is attractive for access, but access is not the same as clinical readiness. This evidence-first analysis examines which tests are mature enough for everyday care, where validation and equity gaps remain, and how patients and clinicians should judge the next wave of pharmacy diagnostics announcements. Sarissa Biomedical Diagnostics and Primary Care Sat, 07 Nov 2026 21:57:42 GMT https://sarissa-biomedical.com/winter-virus-dashboards-population-compass-gp-appointment-2026/ https://sarissa-biomedical.com/winter-virus-dashboards-population-compass-gp-appointment-2026/ As UKHSA, NHS England and local systems publish winter respiratory data for 2026–27, patients and clinicians need to read the numbers at the right scale. Dashboards describe population pressure and trends; they cannot diagnose an individual cough, sore throat or sickness bug. This guide explains how to use the data sensibly when booking or attending a GP appointment. Sarissa Biomedical Public Health Surveillance Sat, 07 Nov 2026 21:57:42 GMT